Dihydroartemisinin treatment exhibits antitumor effects in glioma cells through induction of apoptosis

Xu,Chun‑Hua; Liu,Yue; Xiao,Li‑Min; Guo,Chang‑Gui; Zheng,Su‑Yue; Zeng,Er‑Ming; Li,Dong‑Hai

doi:10.3892/mmr.2017.7832

Dihydroartemisinin treatment exhibits antitumor effects in glioma cells through induction of apoptosis

Authors:
- Chun‑Hua Xu
- Yue Liu
- Li‑Min Xiao
- Chang‑Gui Guo
- Su‑Yue Zheng
- Er‑Ming Zeng
- Dong‑Hai Li
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: October 19, 2017 https://doi.org/10.3892/mmr.2017.7832
Pages: 9528-9532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of dihydroartemisinin on the proliferation of chemotherapy‑resistant C6 rat glioma cells. The results revealed that incubation of C6 glioma cells with a range of dihydroartemisinin concentrations for 48 h led to a significant (P<0.02) reduction in the cell number. There was a ‑0.8-fold reduction in the cell count following treatment with 20 µM dihydroartemisinin when compared with the control cultures. Analysis of DNA synthesis using bromodeoxyuridine (BrdU) staining demonstrated a reduction in the BrdU‑labeling index (LI) following treatment with 20 µM dihydroartemisinin. There was a 6‑fold reduction in the BrdU‑LI compared with the control cultures. Incubation of the C6 glioma cells with dihydroartemisinin led to a concentration dependent reduction in the level of cyclic adenosine 3',5'‑monophosphate following 48 h. The percentage of apoptotic cells in the cultures incubated with 20 µM dihydroartemisinin was 54.78% compared with 2.57% in the control cultures. Incubation of the C6 glioma cells with dihydroartemisinin for 48 h led to a reduction in the percentage of cells in G2/M phase with an increase in G0/G1 phase. The control cells exhibited spindle‑shaped morphology and were actively undergoing mitosis following 48 h of culture. The morphological characteristics of the cells treated with dihydroartemisinin were demonstrated to be round with small surface projections. Therefore, treatment of glioma cells with dihydroartemisinin exhibited an antitumor effect by the induction of apoptosis. Therefore, dihydroartemisinin should be evaluated further in the animal models for the treatment of glioma.

View Figures

View References

1	Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
2	Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics and biology of a grave matter. Genes Dev. 15:1311–1333. 2001. View Article : Google Scholar : PubMed/NCBI
3	Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK and Prados MD: Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 60:353–357. 2004. View Article : Google Scholar : PubMed/NCBI
4	Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW and Borkowf CB: Phase II trial of thalidomide and carmustine for patients with recurrent highgrade gliomas. J Clin Oncol. 21:2299–2304. 2003. View Article : Google Scholar : PubMed/NCBI
5	Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N and Wheeler HR: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 54:31–38. 2001. View Article : Google Scholar : PubMed/NCBI
6	Meshnick SR: Artemisinin: Mechanisms of action, resistance and toxicity. Int J Parasitol. 32:1655–1660. 2002. View Article : Google Scholar : PubMed/NCBI
7	O'Neill PM: Medicinal chemistry: A worthy adversary for malaria. Nature. 430:838–839. 2004. View Article : Google Scholar : PubMed/NCBI
8	Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol. 18:767–773. 2001.PubMed/NCBI
9	Huang XJ, Ma ZQ, Zhang WP, Lu YB and Wei EQ: Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol. 59:849–856. 2007. View Article : Google Scholar : PubMed/NCBI
10	Nam W, Tak J, Ryu JK, Jung M, Yook JI, Kim HJ and Cha IH: Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck. 29:335–340. 2007. View Article : Google Scholar : PubMed/NCBI
11	Singh NP and Lai H: Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 70:49–56. 2001. View Article : Google Scholar : PubMed/NCBI
12	Chen T, Li M, Zhang R and Wang H: Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med. 13:1358–1370. 2009. View Article : Google Scholar : PubMed/NCBI
13	O'Reilly T, Wartmann M, Maira SM, Hattenberger M, Vaxelaire J, Muller M, Ferretti S, Buchdunger E, Altmann KH and McSheehy PM: Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol. 55:307–317. 2005. View Article : Google Scholar : PubMed/NCBI
14	Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA and Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62:3729–3735. 2002.PubMed/NCBI
15	Kaygisiz Z, Erkasap N, Yazihan N, Sayar K, Ataoglu H, Uyar R and Ikizler M: Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts. J Physiol Sci. 56:247–251. 2006. View Article : Google Scholar : PubMed/NCBI
16	Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:139–145. 2000.PubMed/NCBI
17	Yu C, Krystal G, Dent P and Grant S: Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res. 8:2976–2984. 2002.PubMed/NCBI
18	Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D and Lahav M: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 92:1881–1891. 2005. View Article : Google Scholar : PubMed/NCBI
19	Sokołowska P and Nowak JZ: Constitutive activity of beta-adrenergic receptors in C6 glioma cells. Pharmacol Rep. 57:659–663. 2005.PubMed/NCBI
20	Grobben B, De Deyn PP and Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 310:257–270. 2002. View Article : Google Scholar : PubMed/NCBI
21	Jaiswal BS and Conti M: Calcium regulation of the soluble adenylyl cyclase expressed in mammalian spermatozoa. Proc Natl Acad Sci USA. 100:pp. 10676–10681. 2003; View Article : Google Scholar : PubMed/NCBI
22	Baillie GS and Houslay MD: Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol. 17:129–134. 2005. View Article : Google Scholar : PubMed/NCBI
23	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
24	Antonsson B and Martinou JC: The Bcl-2 protein family. Exp Cell Res. 256:50–57. 2000. View Article : Google Scholar : PubMed/NCBI
25	Salvesen GS and Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell. 91:443–446. 1997. View Article : Google Scholar : PubMed/NCBI